Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 5/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186879 | 1.00 | GRIA2 (0.40) | GRIA2GRIA4HDAC3HDAC1HDAC7 | |
| SCHEMBL2186876 | 1.00 | GRIA2 (0.40) | GRIA2GRIA4HDAC3HDAC1HDAC7 | |
| SCHEMBL2217489 | 0.88 | GRIA2 (0.41) | GRIA2GRIA4KCNH2APP | |
| SCHEMBL2215723 | 0.88 | GRIA2 (0.41) | GRIA2GRIA4KCNH2APP | |
| SCHEMBL2215717 | 0.88 | GRIA2 (0.41) | GRIA2GRIA4KCNH2APP | |
| SCHEMBL2189266 | 0.87 | GRIA2 (0.31) | GRIA2KCNH2 | |
| SCHEMBL2189268 | 0.87 | GRIA2 (0.31) | GRIA2KCNH2 | |
| SCHEMBL2190948 | 0.87 | GRIA2 (0.31) | GRIA2KCNH2 | |
| SCHEMBL2189055 | 0.86 | GRIA2 (0.39) | GRIA2GRIA4KCNH2 | |
| SCHEMBL2189970 | 0.86 | GRIA2 (0.39) | GRIA2GRIA4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361246-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | Pfizer Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2011-07-14 | — | — | US | disclosed |
| WO-2010038167-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | PFIZER INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | GRIK5, GABRE, GRIK2 | GRIA2 34/4885GRIA4 25/4885HDAC3 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.